The announcement that a clinical trial of BenlystaTM, the lupus drug from Human Genome Sciences, Inc. (HGSI), is showing positive results has sent the company’s stock soaring. This is good news for both lupus sufferers and investors, but can the company sustain its newly polished image? After decades of disappointing results from apparently promising lupus drugs, optimism is finally warranted. Lupus is an autoimmune disease, in which the body attacks itself. The vast majority of sufferers are women, and symptoms include fatigue, rashes, joint pain and swelling, and lesions of the skin and mouth. The disease often attacks internal organs, eventually leading to death. Human Genome Sciences’ Benlysta significantly reduced patient symptoms, increasing quality of life and decreasing the need for steroids. Sign up now for PowerOptions 14-day free trial There are up to 1.5 million lupus patients in the US, and millions more worldwide, who may benefit if a...